Drug Profile
Ovarian cancer vaccine - NuGenerex Immuno-Oncology
Alternative Names: AE-O vaccine; Her-2/neu combo vaccineLatest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Antigen Express
- Developer NuGenerex Immuno-Oncology
- Class Cancer vaccines; Conjugate vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Ovarian-cancer(Combination therapy) in USA (Parenteral)
- 26 Apr 2016 Phase I development is ongoing in USA
- 07 Aug 2008 Phase-I clinical trials in Ovarian cancer (combination therapy) in USA (Parenteral)